Jin Lu, MD

Company snapshot

Jin Lu, MD is a pharma organization headquartered in CN. Primary therapeutic focus areas include Systemic Amyloidosis. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Jin Lu, MD. Not investment advice.

• What is Jin Lu, MD?

  Jin Lu, MD is a pharma organization headquartered in CN. Primary therapeutic focus areas include Systemic Amyloidosis. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• Is Jin Lu, MD publicly traded?

  Jin Lu, MD appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Jin Lu, MD develop or market?

  We link 1 drug profile(s) where Jin Lu, MD is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/jin-lu-md#company-drugs.

• What are the latest developments for Jin Lu, MD?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Jin Lu, MD focus on?

  Jin Lu, MD focuses on Systemic Amyloidosis based on our analysis of their pipeline programs and drug development activities.